z-logo
open-access-imgOpen Access
What Is New Since the Last (1999) Canadian Asthma Consensus Guidelines?
Author(s) -
LouisPhilippe Boulet,
Tony R. Bai,
Allan B. Becker,
Denis Bérubé,
Robert Beveridge,
Dennis Bowie,
Kenneth R. Chapman,
Johanne Côté,
Donald W. Cockcroft,
Francine M. Ducharme,
Pierre Ernst,
J. Mark FitzGerald,
Thomas Kovesi,
Richard V. Hodder,
Paul M. O’Byrne,
Brian H. Rowe,
Malcolm R. Sears,
F. Estelle R. Simons,
Sheldon Spier
Publication year - 2001
Publication title -
canadian respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.675
H-Index - 53
eISSN - 1916-7245
pISSN - 1198-2241
DOI - 10.1155/2001/278435
Subject(s) - medicine , asthma , asthma management , intensive care medicine , inhaled corticosteroids , emergency department , montelukast , medline , leukotriene , immunology , nursing , political science , law
The objective of the present document is to review the impact of new information on the recommendations made in the last (1999) Canadian Asthma Consensus Guidelines. It includes relevant published studies and observations or comments regarding what are considered to be the main issues in asthma management in children and adults in office, emergency department, hospital and clinical settings. Asthma is still insufficiently controlled in a large number of patients, and practice guidelines need to be integrated better with current care. This report re-emphasises the need for the following: objective measures of airflow obstruction to confirm the diagnosis of asthma suggested by the clinical evaluation; identification of contributing factors; and the establishment of a treatment plan to rapidly obtain and maintain optimal asthma control according to specific criteria. Recent publications support the essential role of asthma education and environmental control in asthma management. They further support the role of inhaled corticosteroids as the mainstay of anti-inflammatory therapy of asthma, and of both long acting beta2-agonists and leukotriene antagonists as effective means to improve asthma control when inhaled corticosteroids are insufficient. New developments, such as combination therapy, and recent major trials, such as the Children's Asthma Management Project (CAMP) study, are discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom